Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypofractionated vs Hyperfractionated RT in Limited-Stage SCLC
NCT04543890Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- May 2018
- Primary completion
- Jun 2023
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial (2 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Progression-Free Survival at 2 years. Status: unknown.
Beyond the preview
Go deeper on NCT04543890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04543890.